Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.
暂无分享,去创建一个
H. Schrezenmeier | J. Lee | W. Füreder | S. Rottinghaus | Hubert Schrezenmeier | Anita Hill | Rajendra Pradhan | Jong Wook Lee | Flore Sicre de Fontbrune | Lily Wong Lee Lee | Viviani Pessoa | Sandra Gualandro | Wolfgang Füreder | Vadim Ptushkin | Scott T Rottinghaus | Lori Volles | Lori Shafner | Rasha Aguzzi | A. Hill | F. Sicre de Fontbrune | R. Pradhan | S. Gualandro | V. Ptushkin | V. Pessoa | R. Aguzzi | L. Shafner | L. Volles | Viviani Pessoa | Lily Wong Lee Lee | J. W. Lee
[1] Zhao-Xue Yu,et al. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action , 2018, PloS one.
[2] Pierre-Yves Dumas,et al. Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no‐treatment study , 2016, American journal of hematology.
[3] P. Densen,et al. Infectious diseases associated with complement deficiencies , 1991, Clinical Microbiology Reviews.
[4] N. Young,et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. , 2008, Blood.
[5] Yi Wang,et al. First in Human Single-Ascending Dose Study: Safety, Biomarker, Pharmacokinetics and Exposure-Response Relationships of ALXN1210, a Humanized Monoclonal Antibody to C5, with Marked Half-Life Extension and Potential for Significantly Longer Dosing Intervals , 2015 .
[6] D. Cella,et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. , 1997, Journal of pain and symptom management.
[7] N. Young,et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. , 2006, The New England journal of medicine.
[8] J. Maciejewski,et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry , 2014, Haematologica.
[9] J. Maciejewski,et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria , 2013, British journal of haematology.
[10] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[11] J. Szer,et al. Immediate, Complete, and Sustained Inhibition of C5 with ALXN1210 Reduces Complement-Mediated Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Interim Analysis of a Dose-Escalation Study , 2016 .
[12] M. Gladwin,et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. , 2005, JAMA.
[13] J. Macneil,et al. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine , 2017, MMWR. Morbidity and mortality weekly report.
[14] J. Inazawa,et al. Genetic variants in C5 and poor response to eculizumab. , 2014, The New England journal of medicine.
[15] R. Brodsky,et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria , 2007, Nature Biotechnology.
[16] T. Kinoshita,et al. Paroxysmal nocturnal haemoglobinuria , 2017, Nature Reviews Disease Primers.
[17] N. Young,et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. , 2007, Blood.
[18] R. Wells,et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. , 2018, Blood advances.
[19] Sung-Soo Yoon,et al. Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry , 2016, Journal of Korean medical science.
[20] H. Echizen,et al. Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria. , 2016, Biological & pharmaceutical bulletin.
[21] W. Gregory,et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. , 2010, Blood.
[22] D. Cella,et al. Fatigue in cancer patients compared with fatigue in the general United States population , 2002, Cancer.
[23] Sung-Soo Yoon,et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry , 2013, International Journal of Hematology.
[24] J. Szer,et al. Clinical course and disease burden in patients with paroxysmal nocturnal hemoglobinuria by hemolytic status. , 2017, Blood cells, molecules & diseases.
[25] C. Bedrosian,et al. Interim Analysis of Safety Outcomes during Treatment with Eculizumab: Results from the International Paroxysmal Nocturnal Hemoglobinuria Registry , 2017 .
[26] R. Wells,et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. , 2019, Blood.
[27] R. Porcher,et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. , 2015, Blood.